ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in Milano, Lombardia

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Renal Cell Carcinoma
Lung Cancer
Squamous Cell Carcinoma

Melanoma trials near Milano, Lombardia, ITA:

Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma (NEO-TIM)

given in combination or sequence may have an anti-tumour activity and may reduce the risk of relapse in patients with high-risk resectable melanoma...

Active, not recruiting
Melanoma
Drug: Cobimetinib 20 MG Oral Tablet
Drug: Atezolizumab 1200 MG in 20 ML Injection

Phase 2

Fondazione Melanoma Onlus

Milano, Italy and 5 other locations

Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma...

Enrolling
Uveal Melanoma
Drug: Darovasertib

Phase 2

Ideaya Biosciences

Milan, Italy and 24 other locations

This is open label, single arm study for pts with stage IIIB-IV melanoma, accordingly with AJCC staging criteria (8th ed.), with potentially...

Active, not recruiting
Melanoma
Drug: Ipilimumab

Phase 2

European Institute of Oncology

Milano, Italy

alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who ...

Enrolling
Melanoma
Unresectable Melanoma
Biological: Pembrolizumab with Optional Crossover Period
Biological: Lifileucel plus Pembrolizumab

Phase 3

Iovance Biotherapeutics

Milan, Italy and 47 other locations

the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant setting of BRAF V600E/K mutant stage IIB/C melanoma...

Active, not recruiting
Melanoma
Drug: Placebo to match Encorafenib ; Placebo to match Binimetinib
Drug: Encorafenib and Binimetinib

Phase 3

Pierre Fabre
Pierre Fabre

Milano, Italy and 154 other locations

medicines (ipilimumab and nivolumab) given for the treatment of melanoma.Melanoma is a type of cancer that starts in the cells that...

Active, not recruiting
Melanoma
Drug: encorafenib
Drug: ipilimumab

Phase 2

Pfizer
Pfizer

Milano, Italy and 62 other locations

therapy per local standard of care (SoC), best supportive care (BSC)) on protocol survivor follow up) in patients with advanced non-ocular melanoma...

Enrolling
Advanced Melanoma
Drug: Tebentafusp
Drug: Tebentafusp with Pembrolizumab

Phase 2, Phase 3

Immunocore
Immunocore

Milano, Italy and 70 other locations

(PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma...

Enrolling
Melanoma
Drug: EU-authorized Nivolumab
Drug: ABP 206

Phase 3

Amgen
Amgen

Milano, Italy and 112 other locations

binimetinib, and pembrolizumab) given together for the treatment of melanoma that:* is advanced or metastatic (spread to other parts of the ...

Active, not recruiting
Melanoma
Drug: Binimetinib
Drug: Encorafenib

Phase 3

Pfizer
Pfizer

Milano, Italy and 227 other locations

This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma...

Enrolling
Mucosal Melanoma
Cutaneous Melanoma
Drug: Nemvaleukin Alfa Intravenous Less Frequent Dosing
Drug: Pembrolizumab

Phase 2

Mural Oncology

Milano, Italy and 43 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems